S. 296 · 112th Congress
Preserving Access to Life-Saving Medications Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 112th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
KlobucharSponsor30 cosponsors · 28 D, 1 R, 1 I
D
Casey
RB
D
Blumenthal
BC
D
Cardin
SB
D
Brown
CS
D
Schumer
JT
D
Tester
CC
D
Coons
DF
D
Feinstein
AF
D
Franken
BM
D
Mikulski
JR
D
Reed
SC
R
Collins
TJ
D
Johnson
JB
D
Bingaman
KG
D
Gillibrand
ML
D
Landrieu
HR
D
Reid
CM
D
McCaskill
JM
D
Merkley
MC
D
Cantwell
DS
D
Stabenow
JS
D
Shaheen
MW
D
Warner
BS
I
Sanders
RD
D
Durbin
FL
D
Lautenberg
PL
D
Leahy
TU
D
Udall
BN
D
Nelson
KC
D
Conrad1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Preserving Access to Life-Saving Medications Act - Amends the Federal Food, Drug, and Cosmetic Act to require a prescription drug manufacturer to notify the Secretary of Health and Human Services (HHS) of a discontinuance, interruption, or other adjustment of the manufacture of the drug that would likely result in a shortage of such drug.
What it does: CRS summary · Introduced in Senate · Feb 7, 2011
Preserving Access to Life-Saving Medications Act - Amends the Federal Food, Drug, and Cosmetic Act to require a prescription drug manufacturer to notify the Secretary of Health and Human Services (HHS) of a discontinuance, interruption, or other adjustment of the manufacture of the drug that would likely result in a shortage of such drug. Requires: (1) six months notice of any discontinuance or planned interruption or adjustment, and (2) notice as soon as practicable after becoming aware of such interruption or adjustment in the case of any other interruption or adjustment. Applies this Act to any approved prescription drug that is not a product that was originally derived from human tissue and was replaced by a recombinant product.
Sets forth the types of adjustment for which a manufacturer must submit notice, including: (1) adjustments related to the supply of raw materials, (2) adjustments to production capabilities, (3) business decisions that may affect the manufacture of the drug, and (4) other adjustments as determined appropriate by the Secretary.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Preserving Access to Life-Saving Medications Act
Latest action (Feb 7, 2011): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Feb 7, 2011
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.